Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment

The New York Times – Business:

While an agency analysis did find signs of Covid “rebound,” the drug significantly reduces hospitalizations and deaths, researchers said.

Carl Zimmer
Author: Carl Zimmer

This post first appeared in The New York Times – Business. Read the original article.

Written by

Carl Zimmer

in

Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Food and Drug Administration, Paxlovid (Drug), Pfizer Inc, United States
←Tauba Auerbach’s Work Might (Possibly) Have Its Own Free Will
For Jean-Yves Thibaudet, a Detour From Classical Is Business as Usual→

More posts

  • Met chief accepts mistakes made over Simon Levy but defends investigation into murders

  • Paul Anthony Kelly Has Found a New Love Story as…a Disney Weddings Model

  • Venice Drama ‘I Matter’, About Roma Experience, Gets Sales Deal

  • Critical former referees add to culture of fear, says retiring Taylor

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube